

**★ AAD 29: Biopsy: Basal Cell Carcinoma Pathology Report - Subtyping Listed –  
National Quality Strategy Domain: Effective Clinical Care**

**DESCRIPTION:**

Basal Cell Carcinoma (BCC) is the most common type of cancer with an incidence rate that continues to rise. Hence documenting the subtype(s) of a basal cell carcinoma (BCC) is critical to allow for best practice and quality of care. With 26 different histological BCC subtypes varying in growth and severity, recording the subtyping allows for the appropriate treatment modality to be used. It is recommended that pathologists catalog patient BCC subtype(s) in order to improve patient management and care. In addition, the subtype is needed in order to risk stratify patients and to administer appropriate treatment.

**INSTRUCTIONS:**

This measure is to be reported by any clinician that performs the histologic interpretation of a cutaneous tissue specimen and the diagnosis is BCC. This measure may be reported by clinicians who perform the quality actions described in the measure based on the services provided and the measure-specific denominator coding.

**Measure Reporting via Registry**

ICD-10-CM diagnosis codes, CPT codes or HCPCS codes and patient demographics are used to identify patients who are included in the measure’s denominator. The listed numerator options are used to report the numerator of the measure.

The quality-data codes listed do not need to be submitted for registry-based submissions; however, these codes may be submitted for those registries that utilize claims data.

**DENOMINATOR:**

All skin specimens diagnosed histologically as cutaneous basal cell carcinoma within the reporting period.

**Diagnosis Codes for Identifying Patients with Basal Cell Carcinoma:**

<b>ICD-10 Codes</b>	<b>Code Description</b>
C44.01	Basal cell carcinoma of skin of lip
C44.111	Basal cell carcinoma of skin of unspecified eyelid, including canthus
C44.1121	Basal cell carcinoma of skin of right upper eyelid, including canthus
C44.1122	Basal cell carcinoma of skin of right lower eyelid, including canthus
C44.1191	Basal cell carcinoma of skin of left upper eyelid, including canthus
C44.1192	Basal cell carcinoma of skin of left lower eyelid, including canthus
C44.211	Basal cell carcinoma of skin of unspecified ear and external auricular canal
C44.212	Basal cell carcinoma of skin of right ear and external auricular canal
C44.219	Basal cell carcinoma of skin of left ear and external auricular canal
C44.310	Basal cell carcinoma of skin of unspecified parts of face
C44.311	Basal cell carcinoma of skin of nose
C44.319	Basal cell carcinoma of skin of other parts of face
C44.41	Basal cell carcinoma of skin of scalp and neck
C44.510	Basal cell carcinoma of anal skin
C44.511	Basal cell carcinoma of skin of breast
C44.519	Basal cell carcinoma of skin of other part of trunk
C44.611	Basal cell carcinoma of skin of unspecified upper limb, including shoulder
C44.612	Basal cell carcinoma of skin of right upper limb, including shoulder
C44.619	Basal cell carcinoma of skin of left upper limb, including shoulder
C44.711	Basal cell carcinoma of skin of unspecified lower limb, including hip
C44.712	Basal cell carcinoma of skin of right lower limb, including hip
C44.719	Basal cell carcinoma of skin of left lower limb, including hip
C44.81	Basal cell carcinoma of overlapping sites of skin

**NUMERATOR:**

Number of skin specimens with a diagnosis of BCC for which the pathology report listed the histopathological BCC subtype.

**Exclusions:**

All cases where the histopathological BCC subtype could not be accurately determined. For all exclusions, an explanation should be provided in the biopsy report (e.g., superficial tissue sampling or fragmentation of the skin specimen).

**Potential Benchmarks:**

>90%

**RATIONALE:**

This measure evaluates the number of pathology reports for basal cell carcinoma (BCC) in which the histopathological BCC subtype is listed. Capturing this would allow for improved patient management and care.

**CLINICAL RECOMMENDATION STATEMENTS:**

This measure will assess the number of skin specimens which are histologically diagnosed as cutaneous Basal Cell Carcinoma with a pathology report listing the histopathological BCC subtype. This is to improve patient management and care through identifying BCC subtypes which can vary in growth and severity.

**COPYRIGHT:**

©American Academy of Dermatology/Association. All rights reserved.

The American Academy of Dermatology and the American Academy of Dermatology Association (collectively AAD/A) own all right, title, and interest in this quality measure. This quality measure is provided solely for the benefit of AAD/A and its members for the purposes specified herein and for other AAD/A purposes. It may not be used by other parties except with prior written approval of the AAD/A.